As the spread of COVID was ramping up in 2020, the Department of Energy launched the National Virtual Biotechnology Laboratory, or NVBL, program with funding from the U.S. government’s CARES Act and began shoring up teams from across DOE’s national laboratory system. The molecular design team took shape, bringing together experimental validation with computation. Within months, they offered five promising drug therapy approaches, each focusing on a unique aspect of the virus’s lifecycle. ORNL scientists contributed to this potential solution with computational data and experimentation. They also contributed to the design, synthesis and testing specific to the papain-like protease, a lesser studied but highly promising approach. The team also characterized the main protease through world-class crystallography and x-ray and neutron experiments by ORNL’s neutron scientists, plus performed inhibitor synthesis experiments at ORNL’s CNMS.
ORAU recently was awarded a contract by the Centers for Disease Control and Prevention Office of Minority Health and Health Equity (OMHHE) to provide technical communications support to the office and three COVID-19 award recipients.
Atkins Nuclear Secured’s Isotek Systems Strengthens Partnership to Advance Cancer Treatment Research
SNC-Lavalin's Isotek Systems, LLC (Isotek) business is pleased to announce that its sales agreement with nuclear innovation company TerraPower, LLC has been expanded to further refine thorium (Th-229). The new agreement will further aid the nuclear innovator in its cancer treatment research by delivering an enhanced purified product and add to the over $90 million taxpayer dollars saved under this innovative public-private partnership.
The University of Tennessee has been on the front lines of the COVID-19 pandemic, from the N95 mask technology to developing systems to quickly and safely screen vaccines, as used by Moderna and Pfizer. These contributions were recently recognized by AUTM’s Better World Project, which named the University of Tennessee Research Foundation (UTRF) as its 2020 Legend Award honoree and spotlighted its work on Gene Pool Innovations for its role in moving academic research from the lab to the marketplace.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.